idea-006 · human · US
For the treatment of adults aged 18 and older with chronic subjective tinnitus of moderate or greater severity, used at home on a prescribed daily schedule under the supervision of a licensed audiologist or physician, as an adjunct to tinnitus counselling.
Finished enough to read, and waiting for you. No department has been asked. 4 of 50 claims verified. Nobody has yet written down what it rests on.
A cheaper second entrant into a new category of tinnitus treatment device. Tinnitus — persistent ringing with no external source — has no cure, and the treatments doctors are told to offer are counselling and hearing aids. In 2023 the FDA (US Food and Drug Administration) created a new device category for a different approach: playing sounds through headphones while delivering small timed electrical pulses to the body, so the brain re-learns to suppress the phantom sound. The device that created that category stimulates the tongue. This one would deliver the electrical half through a skin patch on the face or neck instead, be fitted remotely rather than in a clinic, and sell for less — aimed first at veterans, among whom tinnitus is unusually common.
In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: chronic-subjective-tinnitus-neuromodulation
Two candidate cheque-writers appear in the file, and neither is established as the one that actually clears.
adoption connector refuses to answer.
The chain's weakest link is its first one. Neither cheque-writer is confirmed, and the better-evidenced of the two candidates — the VA channel — is evidenced only for the incumbent, not for this device.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-006 replaces this list with the real one.
Why it scored what it did: intended_use: present, so this row is scorable. Rests entirely on claims 1-3 (DEN210033 (an FDA De Novo decision number) granted; grant created product code QVN; a De Novo grantee is available as a predicate). claim 2verified is single-point-of-failure: if QVN does not exist…the rest of this reasoning
the 510(k) route does not exist and the file collapses to a De Novo. Score is deliberately mid-low to hold the two branches of claim 15unconfirmed open rather than resolve them — the trigeminal/cervical electrode substituted for the predicate's intraoral tongue electrode is a different stimulation site with different technological characteristics, the classic NSE trigger. claim 5verified (874.3400 fallback) is real but sound-only, and trades the therapeutic relief claim for a masking claim, so it does not rescue this score.
What would settle it: openFDA classification, regulation and De Novo lookups (free) already settled claims 1-4. What remains is a clearance-summary read on any future QVN 510(k) K-number for a non-intraoral electrode — same free source, once one exists to check.
Why it scored what it did: claim 7unconfirmed — the Generator found no tinnitus-device-specific CPT (Current Procedural Terminology) or HCPCS (Healthcare Common Procedure Coding System) code and expects self-pay or institutional purchase. claim 7unconfirmed is stated as an absence, and an absence found by web search is not an absence in the code set, so this…the rest of this reasoning
score reflects "no pathway identified," not "no pathway exists." The only positive signal is claim 9unconfirmed (predicate already available to veterans through VA), which is trade-press sourced and whose terms — national contract, per-site purchase, or pilot — are unknown and are the whole value of the claim. claim 17unconfirmed (patients paying several thousand dollars out of pocket for a non-curative treatment) is an explicit assumption and is unverifiable by design; it contributes nothing here.
What would settle it: HCPCS/coverage/payment code lookups are free once a candidate code is named (CPT itself is licensed and unverifiable by connector). Otherwise human-attached: the VA Federal Supply Schedule contract listing and the predicate's published US…the rest of this gap analysis
price.
Why it scored what it did: Claims 10-12, all three of which the Generator states as assumptions or explicit non-numbers: the moderate-or-greater-severity population (claim 10unconfirmed) has no figure at all, price (claim 11unconfirmed) is a $2,000-$4,000 guess anchored to hearing aids…the rest of this reasoning
without looking up the predicate, and addressable share (claim 12unconfirmed) is a low-single-digit assumption. claim 8unconfirmed (3.2-3.5M service-connected tinnitus disabilities) is the strongest commercial fact in the file but is a disability-compensation count, not a market size and not the indicated population — it is a floor on one channel's reachable population, in the same way a Medicare procedure volume is a floor and not a TAM (total addressable market). Score reflects a plausibly large category with every component of the arithmetic unquantified.
What would settle it: Three human-attached primaries, no connector can close any of them: the VBA Annual Benefits Report PDF (claim 8unconfirmed), a severity-stratified NHANES-based tinnitus prevalence study (claim 10unconfirmed), and the predicate's published US price list (claim…the rest of this gap analysis
11).
Why it scored what it did: No claim in this file addresses FTO (freedom to operate), patents, or blocking IP (intellectual property). Not scored, and not scoreable: there is nothing to rest a number on, and guessing here would manufacture evidence for one of the four factors the Stage 5 hard gate reads.…the rest of this reasoning
This is a generation gap, not a weak score — a follower candidate entering a category the incumbent defined by De Novo (claim 16unconfirmed) is exactly the shape where a blocking bimodal-stimulation family is most likely, so the absence is conspicuous. Flagged for the Generator/Scout before or alongside the Verifier pass.
What would settle it: A free USPTO (United States Patent and Trademark Office) Patent Public Search (assignee "Neuromod Devices" and bimodal/trigeminal-stimulation art) to find a candidate patent number, then a per-family patent-connector check — both free, but this is a Scout work item to run first.
Why it scored what it did: claim 16unconfirmed (incumbent holds first-mover position, a published pivotal trial and an established VA relationship) plus the Generator's design rationale: the sole differentiator is the non-intraoral electrode site, and that same substitution is…the rest of this reasoning
the largest threat to the 510(k) route. So the one thing that would distinguish the product is also the thing that costs the cheap pathway. With FTO unclaimed there is no IP-side moat evidence in the file either, and claim 4unconfirmed leaves open that other followers may already be cleared.
What would settle it: Downstream of the FTO patent search above. Also a free openFDA clearances re-check on QVN to see if a follower has cleared since the 2026-08-23 read.
Why it scored what it did: Claims 13-14. claim 13unconfirmed establishes bibliographic existence only of class-level evidence for the predicate's tongue-stimulation configuration — effect size, comparator and durability are all unread. claim 14unconfirmed states plainly that transfer…the rest of this reasoning
of the bimodal-plasticity rationale to a trigeminal/cervical cutaneous electrode is an open scientific question rather than an engineering detail. Score credits a mechanism plausible at class level while withholding credit for the configuration this candidate actually proposes, which has no cited evidence at any level.
What would settle it: Free PubMed literature-detail pulls on the claim-13 PMIDs for effect size, comparator and durability, plus a literature/trials search for any non-intraoral-electrode study — all free scans, Stage 0 only, not verification.
Why it scored what it did: claim 15unconfirmed, which is explicitly two-branched: low-single-digit millions and 18-30 months if the 510(k) holds, versus mid-eight-figures and 4+ years if FDA finds the electrode-site change not substantially equivalent. The score prices the…the rest of this reasoning
uncertainty rather than picking a branch — the branch probability is set by Factor 1 and is precisely what is unknown, and a single number here would hide roughly a 10x cost spread and a 2x calendar spread.
What would settle it: Indirectly, a free clearance-summary read once a QVN K-number exists. Directly, an FDA Pre-Submission (Q-Sub) response on the electrode-site change, obtained through a paid regulatory consultant.
Why it scored what it did: claim 16unconfirmed — incumbent De Novo grantee with first-mover position, published pivotal trial and existing VA relationship; any follower arrives second into a category the incumbent defined. claim 4unconfirmed notes the follower-clearance question cuts…the rest of this reasoning
both ways: a cleared 510(k) under QVN would prove the route works and simultaneously prove the Generator is not the first follower either. High intensity, so a low factor score.
What would settle it: Free openFDA re-checks on QVN clearances and recalls, plus a trials search for who else is active — all Stage 0 scans, pointers not verification.
Why it scored what it did: Not scored. No claim in this file speaks to portfolio fit, and no artifact in this repo defines the portfolio this candidate would sit in, so there is nothing to score against. Recording it blank rather than guessing keeps it visible as a…the rest of this reasoning
missing input instead of inventing a hero-bet-vs-spoke judgement the pipeline has no basis for.
What would settle it: A Tier 3 human input, not a connector read: a stated portfolio thesis and current allocation from whoever owns capital allocation, supplied at Stage 6 shortlist review.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-006 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
Read the posted results of NCT03621735 (a ClinicalTrials.gov registration number) — a completed University of Michigan randomized crossover trial of non-intraoral auditory-somatosensory bimodal stimulation, 100 participants actual, hasResults=true claim 29unconfirmed. The file's own unresolved-claims analysis names it in exactly these terms: for the mechanism-transfer question "the settling artifacts are human: NCT03621735 ... is the first read, and an FDA Pre-Submission written response is what actually prices the NSE branch." A free registry record with outcome data already public, bearing on the branch point that decides whether the capital requirement is low single-digit millions or mid-eight figures. Selected from that gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
Evaluated 2026-08-23 against the Verified Composite above, using verified claims only. The Stage 2 draft table was not consulted. Unchecked boxes below mean the condition did not fire — in this file, in every case, because the data the condition reads does not exist yet. A condition that cannot be evaluated is not a condition that passed.
unconfirmed for
three different reasons: unverifiable-by-design, missing cache, and no VA connector exists).
Undefined, not low; not substituted with a 0.
unverifiable by design and the VA population claim was never checked — nothing in this
repo reads VA data. Note the standing caveat that would survive even if it resolved: a count
of service-connected tinnitus disabilities is a compensation count, not the indicated
population and not a market size.
patent to look up
(and PATENTSVIEW_API_KEY is unset regardless). For a deliberate fast-follower into a
classification an incumbent created by De Novo, a blocking family is exactly the risk one
would check first, and it is unexamined in both directions.
Every one of the three kill conditions is written over a core factor — Regulatory, Reimbursement, TAM, FTO. Of those four, exactly one (Regulatory, 3/5) has a verified claim behind it, and it sits above its floor. The other three — the three that actually decide this gate — are blank. So the gate is not reporting that this candidate survived scrutiny; it is reporting that the scrutiny the gate performs has nothing to read. Recording that distinction is the whole point of separating queued-research from gated-out: "we don't know yet" is not "the answer is no."
procedures connector could not run (missing cache), and the VA figure that would matter is not a Medicare quantity at all.
status: set to queued-research; stage: stays verified — the
Verifier attempted every claim, so the pass is complete and must not be regressed.
wrapped is not an approval — it means a human can now read this.
No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-006 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-006 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A cheaper second entrant into a new category of tinnitus treatment device. Tinnitus — persistent ringing with no external source — has no cure, and the treatments doctors are told to offer are counselling and hearing aids. In 2023 the FDA created a new device category for a different approach: playing sounds through headphones while delivering small timed electrical pulses to the body, so the brain re-learns to suppress the phantom sound. The device that created that category stimulates the tongue. This one would deliver the electrical half through a skin patch on the face or neck instead, be fitted remotely rather than in a clinic, and sell for less — aimed first at veterans, among whom tinnitus is unusually common.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Read the posted results of NCT03621735 — a completed University of Michigan randomized crossover trial of non-intraoral auditory-somatosensory bimodal stimulation, 100 participants actual, hasResults=true claim 29unconfirmed. The file's own unresolved-claims analysis names it in exactly these terms: for the mechanism-transfer question "the settling artifacts are human: NCT03621735 ... is the first read, and an FDA Pre-Submission written response is what actually prices the NSE branch." A free registry record with outcome data already public, bearing on the branch point that decides whether the capital requirement is low single-digit millions or mid-eight figures. Selected from that gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 4 of 41 claims verified, 37 unconfirmed, none refuted. 7 of 9 factors carry a score in the Stage 2 triage table and 3 of 4 core factors do; the remaining rows carry named gaps rather than blanks.
All four verified claims are regulatory: the De Novo grant and its date claim 1verified, the QVN classification it created claim 2verified, and two facts about the adjacent tinnitus-masker regulation claim 5verified, claim 6verified. They establish that the category exists and how FDA thinks about it. None of them touches the question the candidate itself calls its central risk — whether the mechanism survives moving off the tongue.
Thirteen claims were added by the research lane since 2026-08-24 and not one moved a tag, because they are literature, registry records and company press, none of which any connector here can verify. They nonetheless changed this packet substantially, and a Stage 6 reader should read the change as one finding rather than several: the category's evidence turns out to be good, and all of it belongs to somebody else.
The category is attractive. The treatments the 2014 AAO-HNSF guideline actually recommends underperform on their own measures: a Cochrane review of CBT (28 studies, n=2733) found a mean Tinnitus Handicap Inventory reduction of 5.65 points, below the review's own 7-point minimal clinically important difference claim 35unconfirmed, and a Cochrane review of sound therapy (8 studies, n=590) found no evidence that hearing aids, sound generators or combination devices beat waiting-list control, placebo or education-only claim 36unconfirmed. That guideline contains no recommendation addressing bimodal neuromodulation at all claim 39unconfirmed.
The incumbent owns it. A 326-adult randomized double-blinded trial reported a Cohen's d of -0.87 to -0.92 on the THI at 12 weeks, P<.001 claim 31unconfirmed. A 220-patient US real-world chart review reported a 91.5% responder rate, 95% CI 86.9%-94.5% claim 33unconfirmed. A randomized settings trial reported 83.8% compliance claim 32unconfirmed. And per company press materials the incumbent has held a VA Federal Supply Schedule 65 II A contract since 2024-06-17, extended beyond VA to Department of Defense, Bureau of Prisons, Indian Health Services and Public Health Service beneficiaries claim 40unconfirmed.
That last item answered the previous build's desirability load-bearing condition — whether the VA buys in this category — and answering it moved the question rather than closing it. The channel is open and occupied, so what this candidate now needs to know is whether a second, cheaper device gets ordered when the first is already on contract with a pivotal trial behind it. The file classifies that as evidence class 3, a stakeholder-future claim the adoption connector refuses, so no tooling will ever resolve it claim 41unconfirmed. It needs VA audiologists asked.
Three cautions. The FSS award is sourced to a company press release, not a government record claim 40unconfirmed, and no connector here reads VA contracting — it should be confirmed against the VA National Acquisition Center's own listing before anything is built on it. The empirical case for the follower route is three years of silence in a classification created in March 2023 claim 4unconfirmed, which reads differently now that the incumbent spent those years compounding evidence and channel. And FTO is unexamined rather than clear claim 28unconfirmed — never asked, on the rubric's one automatic-kill factor, against an incumbent whose patent position is the obvious blocking surface for a strategy that is explicitly to follow it.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 2 | intended_use: present, so this row is scorable. Rests entirely on claims 1-3 (DEN210033 granted; grant created product code QVN; a De Novo grantee is available as a predicate). claim 2verified is single-point-of-failure: if QVN does not exist…the rest of this reasoningthe 510(k) route does not exist and the file collapses to a De Novo. Score is deliberately mid-low to hold the two branches of claim 15unconfirmed open rather than resolve them — the trigeminal/cervical electrode substituted for the predicate's intraoral tongue electrode is a different stimulation site with different technological characteristics, the classic NSE trigger. claim 5verified (874.3400 fallback) is real but sound-only, and trades the therapeutic relief claim for a masking claim, so it does not rescue this score. | openFDA classification, regulation and De Novo lookups (free) already settled claims 1-4. What remains is a clearance-summary read on any future QVN 510(k) K-number for a non-intraoral electrode — same free source, once one exists to check. |
| Reimbursement pathway | 1 | claim 7unconfirmed — the Generator found no tinnitus-device-specific CPT or HCPCS code and expects self-pay or institutional purchase. claim 7unconfirmed is stated as an absence, and an absence found by web search is not an absence in the code set, so this…the rest of this reasoningscore reflects "no pathway identified," not "no pathway exists." The only positive signal is claim 9unconfirmed (predicate already available to veterans through VA), which is trade-press sourced and whose terms — national contract, per-site purchase, or pilot — are unknown and are the whole value of the claim. claim 17unconfirmed (patients paying several thousand dollars out of pocket for a non-curative treatment) is an explicit assumption and is unverifiable by design; it contributes nothing here. | HCPCS/coverage/payment code lookups are free once a candidate code is named (CPT itself is licensed and unverifiable by connector). Otherwise human-attached: the VA Federal Supply Schedule contract listing and the predicate's published US…the rest of this gap analysisprice. |
| TAM | 2 | Claims 10-12, all three of which the Generator states as assumptions or explicit non-numbers: the moderate-or-greater-severity population (claim 10unconfirmed) has no figure at all, price (claim 11unconfirmed) is a $2,000-$4,000 guess anchored to hearing aids…the rest of this reasoningwithout looking up the predicate, and addressable share (claim 12unconfirmed) is a low-single-digit assumption. claim 8unconfirmed (3.2-3.5M service-connected tinnitus disabilities) is the strongest commercial fact in the file but is a disability-compensation count, not a market size and not the indicated population — it is a floor on one channel's reachable population, in the same way a Medicare procedure volume is a floor and not a TAM. Score reflects a plausibly large category with every component of the arithmetic unquantified. | Three human-attached primaries, no connector can close any of them: the VBA Annual Benefits Report PDF (claim 8unconfirmed), a severity-stratified NHANES-based tinnitus prevalence study (claim 10unconfirmed), and the predicate's published US price list (claim…the rest of this gap analysis11). |
| FTO / IP | — | No claim in this file addresses FTO, patents, or blocking IP. Not scored, and not scoreable: there is nothing to rest a number on, and guessing here would manufacture evidence for one of the four factors the Stage 5 hard gate reads.…the rest of this reasoningThis is a generation gap, not a weak score — a follower candidate entering a category the incumbent defined by De Novo (claim 16unconfirmed) is exactly the shape where a blocking bimodal-stimulation family is most likely, so the absence is conspicuous. Flagged for the Generator/Scout before or alongside the Verifier pass. | A free USPTO Patent Public Search (assignee "Neuromod Devices" and bimodal/trigeminal-stimulation art) to find a candidate patent number, then a per-family patent-connector check — both free, but this is a Scout work item to run first. |
| Moat / defensibility | 1 | claim 16unconfirmed (incumbent holds first-mover position, a published pivotal trial and an established VA relationship) plus the Generator's design rationale: the sole differentiator is the non-intraoral electrode site, and that same substitution is…the rest of this reasoningthe largest threat to the 510(k) route. So the one thing that would distinguish the product is also the thing that costs the cheap pathway. With FTO unclaimed there is no IP-side moat evidence in the file either, and claim 4unconfirmed leaves open that other followers may already be cleared. | Downstream of the FTO patent search above. Also a free openFDA clearances re-check on QVN to see if a follower has cleared since the 2026-08-23 read. |
| Mechanism & clinical risk | 2 | Claims 13-14. claim 13unconfirmed establishes bibliographic existence only of class-level evidence for the predicate's tongue-stimulation configuration — effect size, comparator and durability are all unread. claim 14unconfirmed states plainly that transfer…the rest of this reasoningof the bimodal-plasticity rationale to a trigeminal/cervical cutaneous electrode is an open scientific question rather than an engineering detail. Score credits a mechanism plausible at class level while withholding credit for the configuration this candidate actually proposes, which has no cited evidence at any level. | Free PubMed literature-detail pulls on the claim-13 PMIDs for effect size, comparator and durability, plus a literature/trials search for any non-intraoral-electrode study — all free scans, Stage 0 only, not verification. |
| Capital intensity & time-to-revenue | 2 | claim 15unconfirmed, which is explicitly two-branched: low-single-digit millions and 18-30 months if the 510(k) holds, versus mid-eight-figures and 4+ years if FDA finds the electrode-site change not substantially equivalent. The score prices the…the rest of this reasoninguncertainty rather than picking a branch — the branch probability is set by Factor 1 and is precisely what is unknown, and a single number here would hide roughly a 10x cost spread and a 2x calendar spread. | Indirectly, a free clearance-summary read once a QVN K-number exists. Directly, an FDA Pre-Submission (Q-Sub) response on the electrode-site change, obtained through a paid regulatory consultant. |
| Competitive intensity | 1 | claim 16unconfirmed — incumbent De Novo grantee with first-mover position, published pivotal trial and existing VA relationship; any follower arrives second into a category the incumbent defined. claim 4unconfirmed notes the follower-clearance question cuts…the rest of this reasoningboth ways: a cleared 510(k) under QVN would prove the route works and simultaneously prove the Generator is not the first follower either. High intensity, so a low factor score. | Free openFDA re-checks on QVN clearances and recalls, plus a trials search for who else is active — all Stage 0 scans, pointers not verification. |
| Strategic fit & portfolio balance | — | Not scored. No claim in this file speaks to portfolio fit, and no artifact in this repo defines the portfolio this candidate would sit in, so there is nothing to score against. Recording it blank rather than guessing keeps it visible as a…the rest of this reasoningmissing input instead of inventing a hero-bet-vs-spoke judgement the pipeline has no basis for. | A Tier 3 human input, not a connector read: a stated portfolio thesis and current allocation from whoever owns capital allocation, supplied at Stage 6 shortlist review. |
All eight wrap criteria are met.
Source file: knowledge-base/candidates/idea-006.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md